AASLD News

This morning the American Association for the Study of Liver Diseases (AASLD) unintentionally released an acknowledgment of a positive FDA ruling on Madrigal's MASH therapy. Like many in the field, AASLD is anticipating a ruling soon and prepared a statement in advance. Unfortunately, this communication was issued prematurely and in error. We have no knowledge of any FDA ruling and apologize for

We’re excited to announce there’s another opportunity to share your insights and present your findings at Digestive Disease Week® (DDW) 2024 . DDW is now accepting clinical and basic science Late-Breaking Abstract submissions through March 20. Submissions should feature newsworthy, high-impact data that was not available at the general submission deadline. This is a great opportunity to widen your

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) today announced the sunsetting of their esteemed journal, Clinical Liver Disease ( CLD ). First published in 2012, CLD is a multimedia journal that provides education for clinicians diagnosing and managing patients with liver disease. “As we navigate the rapidly evolving landscape of technology and educational

Alexandria, VA – As part of AASLD’s commitment to championing diversity, equity, and inclusion (DEI) within the field of hepatology, AASLD is pleased to announce the inaugural recipient of the Harold Amos Medical Faculty Development Program Hepatology Award, Ashley L. Spann, MD, MSACI of Vanderbilt University Medical Center . Dr. Spann is an Assistant Professor of Medicine in the Division of

Alexandria, VA –AASLD proudly announces the distinguished leadership of Dr. Ray Kim as its 2024 President. Dr. Kim, a renowned hepatologist and esteemed global researcher, assumed the role of President on January 1, bringing his wealth of experience and commitment to advancing liver disease research, education, and improved patient care. W. Ray Kim, MD, MBA, FAASLD currently serves as Professor of

Alexandria, VA – Join Program Chairs Anna Mae Diehl, MD, FAASLD, Mazen Noureddin, MD, MHSc, and AASLD President Ray Kim, MD, MBA, FAASLD to learn about the latest groundbreaking discoveries and practical treatment methods for Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) at the AASLD Emerging Topic Conference (ETC): Precision Medicine in MASLD held on March 8-9 in Las Vegas, NV

Alexandria, VA – The AASLD Foundation proudly announces the commencement of Dr. Kim Brown as its new Chair. As a distinguished leader in the field of hepatology, Dr. Brown brings a wealth of experience and commitment to advancing liver research and education. “I am excited to begin my term as AASLD Foundation Chair spearheading efforts to invest in research and education, and people who are

AASLD members register ahead of the crowd! Discounted rates available through March 13.

AASLD's three practice guidelines on Non-Invasive Liver Disease Assessment (NILDA) are available for public comment through 1/2/24. The draft guidelines are included in three guideline documents expected to be published in early 2024: AASLD Practice Guideline: Blood-Based Non-invasive Liver Disease Assessment of Hepatic Fibrosis and Steatosis . You can provide your comments on this document here

AASLD, ACG, AGA, ASGE and NASPGHAN recognize that the new class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, tirzepatide, exenatide, liraglutide, albiglutide, dulaglutide, and lixisneatide, currently used for treatment of diabetes and/or weight loss, may be associated with delayed gastric emptying. There is concern that this class of medication

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest medical society supporter of liver disease research and training in the United States, announced today it will distribute $2 million in 2023 to nearly 150 grant recipients to support liver-related research, bolster the pipeline of future hepatologists, and increase patient access to specialty

As AASLD President, it is with immense pleasure and pride that I write to you today to inform you of the next steps for the adoption of NAFLD’s new nomenclature: Steatotic Liver Disease (SLD). As you’re likely aware, the decision to adopt the term Steatotic Liver Disease as the preferred nomenclature was the result of extensive global deliberations and consultations by AASLD, EASL and ALEH along

The American Association for the Study of Liver Diseases (AASLD) acknowledges the important open letter by Rainbows in Gastro calling for a collective effort to support the safety and wellbeing of transgender and non-conforming members. We recognize that transgender and non-conforming individuals face unique challenges, including discrimination, stigma, and health disparities, and we are committed

Steatotic liver disease (SLD) is the new overarching term with metabolic dysfunction-associated steatotic liver disease (MASLD) replacing nonalcoholic fatty liver disease (NAFLD) Vienna, Austria, June 24 - At EASL Congress 2023, the multinational liver societies leaders from La Asociación Latinoamericana para el Estudio del Hígado (ALEH), American Association for the Study of Liver Diseases (AASLD